Phase hub
Phase II clinical trial failures
Explore 10,664 stopped phase ii clinical trials with sponsors, indications, and stop-reason signals.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 970 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 5,543
- OTHER/UNKNOWN
- 4,111
- EFFICACY/FUTILITY
- 598
- SAFETY
- 372
- REGULATORY
- 40
Notable sponsors
- M.D. Anderson Cancer Center
- 256
- National Cancer Institute (NCI)
- 251
- Novartis Pharmaceuticals
- 183
- Pfizer
- 121
- Merck Sharp & Dohme LLC
- 115
Related phases
- Phase II
- 8,428
- Phase I
- 2,236
Crawlable stopped-trial records
Open ExploreShowing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I Non-CNS Tumor trial by Genmab. Stop reason: EFFICACY/FUTILITY.
After reviewing all available data from Part 1 of the trial, the Sponsor has decided not to proceed to Part 2 (randomized Phase 2) of the trial due to lack of efficacy
Phase II Medium-chain Acyl-CoA Dehydrogenase Deficiency trial by Jerry Vockley, MD, PhD. Stop reason: OPERATIONAL.
funding was pulled
Phase II Pulmonary Arterial Hypertension trial by Keros Therapeutics, Inc.. Stop reason: SAFETY.
The study was voluntarily terminated early, following a safety review and observation of pericardial effusions.
Phase II Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
End of Initial Phase of Multi-phase protocol
Phase II Lung Adenocarcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
End of Initial Phase of Multi-phase protocol
Phase II Advanced Biliary Tract Cancer(BTC) trial by National Health Research Institutes, Taiwan. Stop reason: OPERATIONAL.
The study was terminated due to administrative reasons following the cancellation of collaboration between the involved parties.
Phase I Non-Small Cell Lung Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Revisions to eligibility/design being made prior to enrollment of first participants.
Phase II Diffuse Large B-Cell Lymphoma trial by Genmab. Stop reason: OTHER/UNKNOWN.
The study was terminated because sufficient data had been collected to meet the objectives of the development program. No new or unexpected safety findings were identified, and the decision to terminate was not related to participant safety.
Phase II Angioimmunoblastic T-cell Lymphoma trial by Alliance for Clinical Trials in Oncology. Stop reason: EFFICACY/FUTILITY.
Interim Analysis
Phase I Advanced Solid Tumor trial by Selecxine. Stop reason: OPERATIONAL.
Business decision
Phase I Multiple Myeloma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Administrative hold pending non-safety related changes to the study design.
Phase II Medium-chain Acyl-CoA Dehydrogenase Deficiency trial by Jerry Vockley, MD, PhD. Stop reason: OPERATIONAL.
Funding was pulled
Phase II Glioma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Study on hold pending possible updates with the team.
Phase I Pancreatic Cancer trial by M.D. Anderson Cancer Center. Stop reason: OPERATIONAL.
PI Request
Phase II Crohn's Disease trial by Pfizer. Stop reason: EFFICACY/FUTILITY.
The study was prematurely discontinued due to a lack of efficacy in sub-study 1
Phase II Alzheimer Disease trial by Merck Sharp & Dohme LLC. Stop reason: OTHER/UNKNOWN.
Termination Notes: Business reason
Phase II Mucinous Adenocarcinoma of the Rectum trial by University of Southern California. Stop reason: OPERATIONAL.
Insufficient Accrual
Phase I HER2-positive Breast Cancer trial by University of Alabama at Birmingham. Stop reason: OPERATIONAL.
Unable to recruit for this study.
Phase II Hodgkin Lymphoma trial by Ranjana Advani. Stop reason: OTHER/UNKNOWN.
Discontinuation of magrolimab development
Phase II PPROM trial by The University of Texas Medical Branch, Galveston. Stop reason: OPERATIONAL.
Low study recruitment
Phase II RSV Infection trial by Gilead Sciences. Stop reason: OPERATIONAL.
Study was terminated by Sponsor; the decision was not due to any safety findings.
Phase I Leukodystrophy, Globoid Cell trial by Gemma Biotherapeutics. Stop reason: OPERATIONAL.
The study was stopped due to changes in the company strategy.
Phase II Post Traumatic Stress Disorder trial by Global Coalition for Adaptive Research. Stop reason: OPERATIONAL.
The trial has been temporarily suspended due to administrative issues
Phase II Post Traumatic Stress Disorder trial by Global Coalition for Adaptive Research. Stop reason: OPERATIONAL.
The trial has been temporarily suspended due to administrative issues
Phase II Prevention of Esophageal Varices trial by Galectin Therapeutics Inc.. Stop reason: REGULATORY.
Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.
Phase II Uterine Leiomyosarcoma trial by M.D. Anderson Cancer Center. Stop reason: OPERATIONAL.
PI Request
Phase II Non-Small Cell Lung Cancer (NSCLC) trial by University Health Network, Toronto. Stop reason: OTHER/UNKNOWN.
Study Terminated Prior to trial activation, due to changes in SOC of the treatment
Phase II Covid19 trial by HonorHealth Research Institute. Stop reason: OPERATIONAL.
Closed due to poor enrollment
Phase I Diastolic Dysfunction trial by Texas Tech University Health Sciences Center. Stop reason: OTHER/UNKNOWN.
Had issue enrolling subjects.
Phase I Solid Tumor, Adult trial by Virginia Commonwealth University. Stop reason: OTHER/UNKNOWN.
Pending amendment approval
Phase II Hidradenitis Suppurativa trial by Insmed Incorporated. Stop reason: EFFICACY/FUTILITY.
Lack of Efficacy
Phase I Advanced Adenocarcinoma trial by University of California, Davis. Stop reason: SAFETY.
Drugs unavailable
Phase II Frailty trial by University of Rochester. Stop reason: OTHER/UNKNOWN.
The study has been suspended by the IRB pending review of a study-related issue
Phase II Myelofibrosis trial by Incyte Corporation. Stop reason: OPERATIONAL.
The decision to close the study was made due to the expiration of remaining drug supply.
Phase I Lymphoma, Non-Hodgkin trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Coronavirus trial by Celularity Incorporated. Stop reason: OPERATIONAL.
Lack of enrollment due to COVID treatment options availability.
Phase II Liver and Intrahepatic Bile Duct Carcinoma trial by OHSU Knight Cancer Institute. Stop reason: OTHER/UNKNOWN.
change in standard-of-care systemic therapy
Phase I Relapsing Multiple Sclerosis (RMS) trial by Cabaletta Bio. Stop reason: OPERATIONAL.
The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the development portfolio.
Phase II Advanced Head and Neck Squamous Cell Carcinoma trial by NRG Oncology. Stop reason: OTHER/UNKNOWN.
End of Initial Phase of Multi-phase protocol; closed for protocol specified analysis
Phase II Osteochondrodysplasia trial by Sanofi. Stop reason: OPERATIONAL.
Sponsor decision. Not related to safety concern.
Phase I Metastatic Castration-Resistant Prostate Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Other - To assess the study's feasibility.
Phase II Renal Angiomyolipomas trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.
target number of subject not reached
Phase II Myocardial Infarction trial by Boehringer Ingelheim. Stop reason: OPERATIONAL.
Sponsor decision
Phase II Groin Injury trial by University Hospital, Bordeaux. Stop reason: OPERATIONAL.
target number of patient not reached and lost of financial supplies
Phase I Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia trial by Nantes University Hospital. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Colorectal Cancer trial by University of Southampton. Stop reason: OPERATIONAL.
funding withdrawal
Phase II Hepatocellular Carcinoma trial by Assistance Publique - Hôpitaux de Paris. Stop reason: OPERATIONAL.
Because patient recruitment was affected by the COVID-19 pandemic, the study sponsor and funding partner halted enrollment at that time to meet contractual obligations
Phase II Myocardial Infarction trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Administrative reasons.
Phase II Prostate Cancer trial by Ivan de Kouchkovsky, MD. Stop reason: OPERATIONAL.
Due to funding
Phase II Ulcerative Colitis trial by AstraZeneca. Stop reason: OPERATIONAL.
Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
Phase II Locally Advanced Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Other - study has reached accrual goal for analysis
Phase II Crohn's Disease trial by AstraZeneca. Stop reason: OPERATIONAL.
Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
Phase I Lung Cancer trial by Shenzhen Geno-Immune Medical Institute. Stop reason: OTHER/UNKNOWN.
combine with NCT03356808
Phase II Ulcerative Colitis trial by AstraZeneca. Stop reason: OPERATIONAL.
Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
Phase II Covid19 trial by PureTech. Stop reason: OTHER/UNKNOWN.
Part A of the study was completed; Part B of the study was terminated
Phase II Prostate Cancer trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.
target number of patients not reached
Phase II Pain, Postoperative trial by University of Florida. Stop reason: OPERATIONAL.
PI left institution.
Phase I Advanced HR+/HER2- Breast Cancer trial by Novartis Pharmaceuticals. Stop reason: OPERATIONAL.
Business decision
Phase I Solid Tumors trial by Amgen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase I GBA1 Parkinson Disease trial by Capsida Biotherapeutics, Inc.. Stop reason: OTHER/UNKNOWN.
Per protocol stopping rule was met for a separate trial for a different disease state and different experimental therapy that utilized a similar technology.
Phase II Pain, Postoperative trial by Rutgers, The State University of New Jersey. Stop reason: OPERATIONAL.
This study never got funded. It is not feasible to conduct this study without funding.
Phase II Respiratory Syncytial Virus Infections trial by Shanghai Ark Biopharmaceutical Co., Ltd.. Stop reason: OPERATIONAL.
The study was terminated early due to COVID-19-related enrollment disruptions, not as a result of any product safety concerns.
Phase II Cystic Fibrosis trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.
Target number of inclusion not reached
Phase II FSGS trial by Apellis Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Study temporarily suspended due to company acquisition and ongoing strategic evaluation, with recruitment challenges including screening failures
Phase II Crohn Disease trial by Mayo Clinic. Stop reason: OPERATIONAL.
Sponsor discontinued placebo. Unable to meet enrollment goals.
Phase I Desmoplastic Small Round Cell Tumor trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Other - Stage 1 has met accrual
Phase II Hepatocellular Carcinoma trial by University of Texas Southwestern Medical Center. Stop reason: OPERATIONAL.
The decision was made to close the study to enrollment due to poor overall accrual and the inability to meet the 31% overall enrollment goal.
Phase II Metastatic Pancreatic Adenocarcinoma trial by Mayo Clinic. Stop reason: OPERATIONAL.
Low/slow accrual
Phase II Multiple Myeloma (MM) trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.
Sponsor Decision
Phase II Glycogen Storage Disease Type IB trial by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Stop reason: OPERATIONAL.
The study was not initiated because the planned prospective design was no longer feasible in routine clinical practice before participant enrollment.
Phase II Membranous Nephropathy trial by Centre Hospitalier Universitaire de Nice. Stop reason: OTHER/UNKNOWN.
Only screenfail during inclusion period
Phase II Panic Disorder trial by HB BioTech, LLC. Stop reason: OPERATIONAL.
Recruitment paused for Data Monitoring Committee (DMC) to review interim analysis data.
Phase I Ovarian Cancer trial by NewLink Genetics Corporation. Stop reason: OPERATIONAL.
Company decision
Phase II Hidradenitis Suppurativa (HS) trial by Boehringer Ingelheim. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Chronic Fatigue Syndrome trial by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland. Stop reason: OTHER/UNKNOWN.
occurrence of scientific risk
Phase II Rheumatoid Arthritis trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
The interim analysis data failed to demonstrate the intended treatment effect.
Phase II Locally Recurrent Skin Squamous Cell Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - safety run-in for initial cohort of participants
Phase I Perinatal Arterial Ischemic Stroke trial by James Baumgartner, MD. Stop reason: SAFETY.
The FDA required a clinical hold for the IND which remained until it was determined that the study would be closed.
Phase I Hepatitis B trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The study was terminated as a strategic decision
Phase II Chronic Myelomonocytic Leukemia trial by M.D. Anderson Cancer Center. Stop reason: OPERATIONAL.
PI request
Phase II Dermatitis, Atopic trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Sponsor decision to early terminate the study following the termination of the parent study (NCT05999799), which met pre-defined futility criterion for efficacy. No safety concerns were identified.
Phase I Cancer trial by Baptist Health South Florida. Stop reason: OPERATIONAL.
Funding
Phase II Colorectal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
New information received
Phase II Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma trial by David Bond, MD. Stop reason: OPERATIONAL.
sponsor decision
Phase I Solid Tumor trial by Servier Bio-Innovation LLC. Stop reason: OPERATIONAL.
Sponsor decision to terminate during Phase 1
Phase II Ulcerative Colitis trial by AbbVie. Stop reason: OPERATIONAL.
Sponsor Decision\_Not Safety Related
Phase II Esophagitis trial by Pfizer. Stop reason: OPERATIONAL.
Pfizer has made an internal business decision to terminate the B1791094 study. This decision was not due to safety concerns or requests from any regulatory authorities.
Phase II Pain Management trial by Wake Forest University Health Sciences. Stop reason: OPERATIONAL.
Study initially suspended following an audit and need of amendment to address deficiencies. PI requested to terminate due to lack of support.
Phase II Metastatic Nasopharyngeal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Scheduled Interim Monitoring
Phase II Breast Cancer trial by Mayo Clinic. Stop reason: OPERATIONAL.
slow accrual; insufficient funding to continue to accrue
Phase II Melanoma trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.
Business Decision
Phase II Recurrent B-Cell Non-Hodgkin Lymphoma trial by University of Washington. Stop reason: OPERATIONAL.
The trial closed early due to slow accrual.
Phase I Hemophilia B trial by Be Biopharma. Stop reason: OPERATIONAL.
The study was terminated due to a strategic business decision and not due to safety concerns
Phase II Unresectable Hepatocellular Carcinoma trial by University of Miami. Stop reason: OPERATIONAL.
Investigator decision
Phase II Metastatic Cancer trial by M.D. Anderson Cancer Center. Stop reason: OPERATIONAL.
PI request
Phase II Myocardial Infarction, Acute trial by University Hospital, Montpellier. Stop reason: OTHER/UNKNOWN.
Inclusion period completed
Phase II Stage IV Colorectal Cancer Positive for BRAF V600E Mutation trial by Northwestern University. Stop reason: OPERATIONAL.
The study was closed due to accrual.
Phase II Alcohol Use Disorder trial by Hôpital le Vinatier. Stop reason: OTHER/UNKNOWN.
Péremption des unités de traitement prévue début juin 2026. Compte tenu des délais de traitement, aucune administration ne sera plus possible après le 1 février 2026. Ces facteurs ne permettent plus de garantir la poursuite des inclusions.
Phase II NSCLC trial by Spectrum Pharmaceuticals, Inc. Stop reason: OPERATIONAL.
Strategic business decision (unrelated to safety)
Phase II Soft Tissue Sarcoma trial by Sun Yat-sen University. Stop reason: OTHER/UNKNOWN.
The study was terminated due to initiation of a new clinical trial with an updated study design.